Generic Antara® Launches
On Friday, February 22, Mylan received final FDA approval and launched the generic equivalent of Lupin’s Antara® (micronized fenofibrate). Annual U.S. brand sales of this product were $53 million.
Antara® is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C) triglycerides (TC), and apollpoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.
